President Donald Trump announced Monday that his administration has reached deals with nine more pharmaceutical companies to offer lower-priced drugs. Under the "most favored nation" pricing system, these companies will sell their drugs to state Medicaid programs at discounts.
The White House stated that these agreements will reduce costs to treat various illnesses, including liver disease, glaucoma, macular degeneration, and Parkinson's disease.
This string of deals builds on the Trump administration's push to link drug prices in the United States to cheaper ones abroad.